ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: Adalimumab
Other: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2020-11-23

Lead Sponsor: AbbVie

Target Recruit Count: 952

Registration Number: NCT02065622

Locations: 🇺🇸
Atlanta Gastro Assoc /ID# 122336, Atlanta, Georgia, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 122183, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh MC /ID# 122331, Pittsburgh, Pennsylvania, United States

and more 170 locations

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2014-02-19

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 300

Registration Number: NCT02066389

Locations: 🇺🇸
C.V. Mehta MD, Med Corporation /ID# 126380, Hemet, California, United States
🇺🇸
Mountain State Clinical Resear /ID# 127089, Clarksburg, West Virginia, United States
🇿🇦
Panorama Medical Centre /ID# 126846, Cape Town, Western Cape, South Africa

and more 60 locations

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: Adalimumab
Biological: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2020-10-05

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT02065557

Locations: 🇦🇺
Womens and Childrens Hospital /ID# 127538, Adelaide, South Australia, Australia
🇺🇸
Children's Ctr Digestive, US /ID# 121855, Atlanta, Georgia, United States
🇺🇸
University of Chicago /ID# 120904, Chicago, Illinois, United States

and more 57 locations

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Phase 1

Completed

Conditions: Relative Bioavailability

Interventions: Drug: ABT-333

First Posted Date: 2014-02-03

Last Posted Date: 2014-02-03

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT02052349

Locations: 🇬🇧
Site Reference ID/Investigator# 118435, Nottingham, United Kingdom

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Phase 1

Completed

Conditions: Absolute Bioavailability

Interventions: Drug: ABT-450/r/ABT-267

First Posted Date: 2014-02-03

Last Posted Date: 2014-02-19

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT02052362

Locations: 🇬🇧
Site Reference ID/Investigator# 118615, Nottingham, United Kingdom

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Upadacitinib
Biological: Pneumococcal 13-valent conjugate vaccine (PCV-13)

First Posted Date: 2014-01-30

Last Posted Date: 2022-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 493

Registration Number: NCT02049138

Locations: 🇺🇸
IRIS Research and Development, LLC /ID# 140362, Plantation, Florida, United States
🇨🇱
Quantum Research /ID# 136188, Puerto Varas, Los Lagos, Chile
🇺🇸
The Center for Rheumatology and Bone Research /ID# 124077, Wheaton, Maryland, United States

and more 121 locations

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Phase 2

Completed

Conditions: Ankylosing Spondylitis (AS)

Interventions: Drug: placebo for risankizumab
Drug: risankizumab

First Posted Date: 2014-01-28

Last Posted Date: 2019-05-31

Lead Sponsor: AbbVie

Target Recruit Count: 159

Registration Number: NCT02047110

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Colon Cancer
Solid Tumors
Breast Cancer
Ovarian Cancer
Gastric Cancer
Lung Cancer

Interventions: Drug: Veliparib
Drug: FOLFIRI
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2014-01-13

Last Posted Date: 2016-09-27

Lead Sponsor: AbbVie

Target Recruit Count: 47

Registration Number: NCT02033551

Locations: 🇪🇸
Site Reference ID/Investigator# 117451, Madrid, Spain
🇺🇸
Site Reference ID/Investigator# 117415, San Antonio, Texas, United States
🇳🇱
Site Reference ID/Investigator# 117338, Maastricht, Netherlands

and more 2 locations

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Phase 3

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin
Drug: Veliparib

First Posted Date: 2014-01-10

Last Posted Date: 2021-01-20

Lead Sponsor: AbbVie

Target Recruit Count: 634

Registration Number: NCT02032277

Locations: 🇺🇸
Lehigh Valley Health Network /ID# 133372, Allentown, Pennsylvania, United States
🇺🇸
Texas Oncology - Medical City Dallas /ID# 126141, Dallas, Texas, United States
🇺🇸
UT Southwestern Medical Center /ID# 133849, Dallas, Texas, United States

and more 155 locations

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Phase 2

Completed

Conditions: Crohn Disease

Interventions: Drug: risankizumab IV
Drug: risankizumab SC
Drug: Placebo

First Posted Date: 2014-01-09

Last Posted Date: 2018-11-23

Lead Sponsor: AbbVie

Target Recruit Count: 121

Registration Number: NCT02031276

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy